Buy Or Sell Opportunity • Nov 11
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 1.7% to €1.75. The fair value is estimated to be €1.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 122% over the last year. Earnings per share has declined by 102%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 58% per annum over the same time period. New Risk • Nov 02
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€404k net loss in 3 years). Market cap is less than US$100m (€58.4m market cap, or US$67.3m). Breakeven Date Change • Sep 11
Forecast breakeven date pushed back to 2027 The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule. Breakeven Date Change • Aug 14
Forecast breakeven date pushed back to 2027 The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule. Breakeven Date Change • Jun 20
Forecast breakeven date pushed back to 2027 The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule. New Risk • Jun 05
New major risk - Revenue and earnings growth Earnings have declined by 7.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€58.4m market cap, or US$66.8m). 공시 • Jun 04
Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025 Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025. New Risk • May 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€502k net loss in 2 years). Market cap is less than US$100m (€59.4m market cap, or US$66.3m). Breakeven Date Change • Apr 24
No longer forecast to breakeven The analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025. Breakeven Date Change • Dec 31
No longer forecast to breakeven The analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025. New Risk • Sep 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€200k net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (€59.3m market cap, or US$65.4m). 공시 • Jun 05
Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024 Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024. Reported Earnings • May 08
Full year 2023 earnings released Full year 2023 results: Revenue: €9.95m (up 49% from FY 2022). Net loss: €4.66m (loss widened 72% from FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. New Risk • Nov 03
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €2.7m Forecast net loss in 1 year: €600k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€600k net loss next year). Market cap is less than US$100m (€58.5m market cap, or US$62.8m). Breakeven Date Change • Nov 03
Forecast to breakeven in 2024 The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests losses will reduce by 78% to 2023. The company is expected to make a profit of €900.0k in 2024. Average annual earnings growth of 99% is required to achieve expected profit on schedule. New Risk • Nov 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.0% average weekly change). Market cap is less than US$100m (€58.5m market cap, or US$62.1m). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Breakeven Date Change • Apr 01
Forecast to breakeven in 2022 The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 111% is required to achieve expected profit on schedule. Breakeven Date Change • Sep 23
Forecast to breakeven in 2022 The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 91% is required to achieve expected profit on schedule. Is New 90 Day High Low • Feb 11
New 90-day low: €1.42 The company is down 12% from its price of €1.62 on 13 November 2020. The Spanish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 10.0% over the same period. Is New 90 Day High Low • Jan 07
New 90-day low: €1.44 The company is down 3.0% from its price of €1.49 on 09 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period. 공시 • Oct 15
Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million. Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million on October 13, 2020. Under the terms of transaction, Vidaro Inversiones purchased a total of 1.11 million securities of Pangaea Oncology at price of €1.36 for each Pangea share.
Vidaro Inversiones S.L. completed the acquisition of 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL on October 13, 2020. Is New 90 Day High Low • Oct 14
New 90-day high: €1.54 The company is up 3.0% from its price of €1.49 on 16 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 14% over the same period. 
